对不起，此内容只适用于English。 For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

In an extraordinary medical first, doctors at the Children’s Hospital of Philadelphia have successfully treated a baby with a rare and life-threatening genetic condition using a customized gene-editing therapy, a groundbreaking development that could transform the future of genetic medicine.

When baby KJ was just a week old, he was diagnosed with CPS1 deficiency, an extremely rare metabolic disorder that prevents the body from processing ammonia, which is a waste product of protein metabolism. Left untreated, ammonia builds up in the blood and can cause severe brain damage or death. The outlook for infants with this condition is often grim: half die within the first week of life.

Initially, KJ’s parents, Kyle and Nicole Muldoon, were offered comfort care given the severity of his diagnosis. Though they did not want their son to suffer, they decided to give their son a fighting chance, and amazingly, KJ went on to make medical history.

Using base editing, a precise form of gene editing that corrects single-letter mutations in DNA, a team of researchers created a personalized treatment designed specifically for KJ’s unique genetic mutation. The therapy used CRISPR technology as a molecular GPS to guide the editor to the exact site in his DNA that needed repair. To protect the fragile therapy on its journey through the bloodstream, the gene-editing components were packaged in lipid molecules and delivered directly to his liver, the organ most affected by the disorder.

There are multiple factors that make KJ’s complex case remarkable, and one is the speed at which this technology was developed. Scientists, doctors, pharmaceutical experts, and regulators worked together at an unprecedented pace. From KJ’s diagnosis to the delivery of the first dose took just a few months, which has traditionally taken the better part of a decade, according to the doctors on the team.

The first dose was administered when KJ was six months old. He slept through the two-hour infusion. Just two weeks later, his body began tolerating more protein, and his medication dosage was halved. Two more infusions followed, and remarkably, KJ has continued to improve. He is meeting developmental milestones, his ammonia levels are stabilizing, and doctors are now preparing for him to leave the hospital and go home soon.

While it’s too soon to know if he will avoid a liver transplant, KJ’s progress is a powerful example of how personalized gene editing could revolutionize treatment for rare genetic disorders. This approach, called “N-of-1” medicine, customizes therapies for individuals based on their specific DNA. It opens the door for future treatments of other conditions, including more common ones like cystic fibrosis and muscular dystrophy.

At The Surrogacy Law Center, we aim to provide our clients with a straightforward breakdown of what might seem to be a complicated and daunting process so that they can enjoy the beautiful experience of bringing a child into the world through assisted reproductive technology. Schedule your consultation today!